ChemoCentryx, Inc. (CCXI) Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research upgraded shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a hold rating to a buy rating in a research report report published on Friday morning. Zacks Investment Research currently has $8.25 target price on the biopharmaceutical company’s stock.
According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “
Several other equities research analysts have also recently issued reports on the company. ValuEngine cut ChemoCentryx from a hold rating to a sell rating in a report on Saturday, October 21st. BidaskClub cut ChemoCentryx from a buy rating to a hold rating in a report on Friday, August 18th. Finally, Cowen and Company reiterated a hold rating on shares of ChemoCentryx in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $8.25.
ChemoCentryx (NASDAQ:CCXI) traded down $0.18 during trading hours on Friday, hitting $7.31. The stock had a trading volume of 57,900 shares, compared to its average volume of 140,787. ChemoCentryx has a 52-week low of $6.13 and a 52-week high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.13. analysts predict that ChemoCentryx will post -0.67 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “ChemoCentryx, Inc. (CCXI) Stock Rating Upgraded by Zacks Investment Research” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/14/chemocentryx-inc-ccxi-stock-rating-upgraded-by-zacks-investment-research.html.
A number of hedge funds have recently bought and sold shares of the stock. Wasatch Advisors Inc. boosted its holdings in ChemoCentryx by 10.3% in the 2nd quarter. Wasatch Advisors Inc. now owns 2,255,438 shares of the biopharmaceutical company’s stock worth $21,111,000 after buying an additional 210,039 shares during the last quarter. Vanguard Group Inc. boosted its holdings in ChemoCentryx by 1.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,212,074 shares of the biopharmaceutical company’s stock worth $11,345,000 after buying an additional 13,344 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in ChemoCentryx by 3.7% in the 2nd quarter. Acadian Asset Management LLC now owns 885,442 shares of the biopharmaceutical company’s stock worth $8,287,000 after buying an additional 31,724 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in ChemoCentryx by 31.0% in the 1st quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock worth $4,489,000 after buying an additional 146,000 shares during the last quarter. Finally, State Street Corp boosted its holdings in ChemoCentryx by 7.0% in the 2nd quarter. State Street Corp now owns 429,088 shares of the biopharmaceutical company’s stock worth $4,016,000 after buying an additional 27,896 shares during the last quarter. Institutional investors own 49.15% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.